{"id":1794,"date":"2024-03-20T17:52:29","date_gmt":"2024-03-20T17:52:29","guid":{"rendered":"https:\/\/stoxpo.com\/?p=1794"},"modified":"2024-03-20T17:52:30","modified_gmt":"2024-03-20T17:52:30","slug":"igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/","title":{"rendered":"IGC Pharma&#8217;s IGC-AD1 Shows Promising Results in Alzheimer&#8217;s Agitation Trial"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Interim Analysis Reveals Statistically Significant Reduction in Agitation Levels<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">IGC Pharma (IGC) has unveiled encouraging findings from its ongoing Phase 2 trial of IGC-AD1 for Agitation in Dementia from Alzheimer\u2019s Disease (AAD). With Alzheimer&#8217;s affecting an estimated 6.7 million Americans in 2023, addressing agitation is crucial, as up to 76% of patients experience this symptom.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The interim analysis showcases a notable reduction in agitation among Alzheimer&#8217;s patients treated with IGC-AD1 compared to those receiving a placebo. Using the Cohen Mansfield Agitation Inventory (CMAI) scale, patients exhibited significantly lower agitation scores as early as week two of the trial.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Key findings include a Cohen\u2019s d effect size of 0.66 at the primary outcome assessment at week six, indicating the superiority of IGC-AD1 over placebo. Additionally, the LS mean difference between active and placebo was -10.45, with a p-value of 0.037.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These promising results underscore the potential of IGC-AD1 to improve patient outcomes in Alzheimer&#8217;s-related agitation. Ram Mukunda, CEO of IGC Pharma, expressed confidence in the clinical profile of IGC-AD1, signaling its potential to drive shareholder value pending further trials.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Read original press release:<a href=\"https:\/\/www.businesswire.com\/news\/home\/20240320069009\/en\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">here<\/mark><\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/xtl-biopharmaceuticals-announces-acquisition-of-the-social-proxy-a-strategic-move-in-ai-data-extraction\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">XTL Biopharmaceuticals Announces Acquisition of The Social Proxy: A Strategic Move in AI Data Extraction<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Interim Analysis Reveals Statistically Significant Reduction in Agitation Levels IGC Pharma (IGC) has unveiled encouraging findings from its ongoing Phase 2 trial of IGC-AD1 for Agitation in Dementia from Alzheimer\u2019s Disease (AAD). With Alzheimer&#8217;s affecting an estimated 6.7 million Americans in 2023, addressing agitation is crucial, as up to 76% of patients experience this symptom. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1796,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[358,309],"tags":[],"coauthors":[453],"class_list":["post-1794","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-micro-cap","category-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IGC Pharma&#039;s IGC-AD1 Shows Promising Results in Alzheimer&#039;s Agitation Trial - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IGC Pharma&#039;s IGC-AD1 Shows Promising Results in Alzheimer&#039;s Agitation Trial - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Interim Analysis Reveals Statistically Significant Reduction in Agitation Levels IGC Pharma (IGC) has unveiled encouraging findings from its ongoing Phase 2 trial of IGC-AD1 for Agitation in Dementia from Alzheimer\u2019s Disease (AAD). With Alzheimer&#8217;s affecting an estimated 6.7 million Americans in 2023, addressing agitation is crucial, as up to 76% of patients experience this symptom. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-20T17:52:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-20T17:52:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/03\/pexels-pixabay-208518-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Liliana Vida\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Liliana Vida\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\\\/\"},\"author\":{\"name\":\"Liliana Vida\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\"},\"headline\":\"IGC Pharma&#8217;s IGC-AD1 Shows Promising Results in Alzheimer&#8217;s Agitation Trial\",\"datePublished\":\"2024-03-20T17:52:29+00:00\",\"dateModified\":\"2024-03-20T17:52:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\\\/\"},\"wordCount\":214,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/pexels-pixabay-208518-scaled.jpg\",\"articleSection\":[\"Micro-Cap\",\"Pharmaceuticals\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\\\/\",\"name\":\"IGC Pharma's IGC-AD1 Shows Promising Results in Alzheimer's Agitation Trial - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/pexels-pixabay-208518-scaled.jpg\",\"datePublished\":\"2024-03-20T17:52:29+00:00\",\"dateModified\":\"2024-03-20T17:52:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/pexels-pixabay-208518-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/pexels-pixabay-208518-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/20\\\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IGC Pharma&#8217;s IGC-AD1 Shows Promising Results in Alzheimer&#8217;s Agitation Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\",\"name\":\"Liliana Vida\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"caption\":\"Liliana Vida\"},\"description\":\"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/stoxpo-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IGC Pharma's IGC-AD1 Shows Promising Results in Alzheimer's Agitation Trial - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/","og_locale":"en_US","og_type":"article","og_title":"IGC Pharma's IGC-AD1 Shows Promising Results in Alzheimer's Agitation Trial - Stoxpo","og_description":"Interim Analysis Reveals Statistically Significant Reduction in Agitation Levels IGC Pharma (IGC) has unveiled encouraging findings from its ongoing Phase 2 trial of IGC-AD1 for Agitation in Dementia from Alzheimer\u2019s Disease (AAD). With Alzheimer&#8217;s affecting an estimated 6.7 million Americans in 2023, addressing agitation is crucial, as up to 76% of patients experience this symptom. [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/","og_site_name":"Stoxpo","article_published_time":"2024-03-20T17:52:29+00:00","article_modified_time":"2024-03-20T17:52:30+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/03\/pexels-pixabay-208518-scaled.jpg","type":"image\/jpeg"}],"author":"Liliana Vida","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Liliana Vida","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/"},"author":{"name":"Liliana Vida","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1"},"headline":"IGC Pharma&#8217;s IGC-AD1 Shows Promising Results in Alzheimer&#8217;s Agitation Trial","datePublished":"2024-03-20T17:52:29+00:00","dateModified":"2024-03-20T17:52:30+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/"},"wordCount":214,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/03\/pexels-pixabay-208518-scaled.jpg","articleSection":["Micro-Cap","Pharmaceuticals"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/","url":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/","name":"IGC Pharma's IGC-AD1 Shows Promising Results in Alzheimer's Agitation Trial - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/03\/pexels-pixabay-208518-scaled.jpg","datePublished":"2024-03-20T17:52:29+00:00","dateModified":"2024-03-20T17:52:30+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/03\/pexels-pixabay-208518-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/03\/pexels-pixabay-208518-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"IGC Pharma&#8217;s IGC-AD1 Shows Promising Results in Alzheimer&#8217;s Agitation Trial"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1","name":"Liliana Vida","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6","url":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","caption":"Liliana Vida"},"description":"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/stoxpo-com\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=1794"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1794\/revisions"}],"predecessor-version":[{"id":1797,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1794\/revisions\/1797"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1796"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=1794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=1794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=1794"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=1794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}